Akanda Reports Q2 Loss, Going Concern Warning, and 5-Month Cash Runway
AKAN is trading near its 52-week low of $2.295 (9.8% above the low) on light trading volume (0.1× avg).
Summary
Akanda filed Q2 2026 results showing a $6.2M net loss, a $9.7M working capital deficit, and cash of only $755K. Management warns of substantial doubt about its ability to continue as a going concern, with about five months of runway.
Key Events · Earnings and Guidance · AKAN
-
Q2 Net Loss of $6.2M
Net loss from continuing operations was $6,246,310 for the six months ended June 30, 2026, versus $1,404,293 in the prior-year period. Revenue of $404,394 came entirely from the First Towers fiber business in Mexico.
-
Going Concern Warning
Management states substantial doubt about the company's ability to continue as a going concern. Cash of $755,238 and expected future revenues are estimated to fund operations for only about five months at the current burn rate.
-
Working Capital Deficit of $9.7M
As of June 30, 2026, current liabilities exceeded current assets by $9,682,542, driven by $7.0M in convertible promissory notes and $3.6M in trade payables.
-
January Notes Converted into 1.03M Shares
Subsequent to June 30, 2026 and through August 26, 2026, holders converted January Notes into 1,030,000 common shares at prices between $4.26 and $5.72, for a total of $4,839,970.
Analysis · AKAN · Life Sciences
Akanda's Q2 2026 financials reveal a $6.2M net loss, a working capital deficit of $9.7M, and only $755K in cash — enough for roughly five months at the current burn rate. Management states substantial doubt about the company's ability to continue as a going concern. This is the first time these numbers have been disclosed, and they materially worsen the survival picture for a company already exiting cannabis and pivoting entirely to its First Towers fiber business.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 37.1% of the 989 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.64%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AKAN was trading at $2.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2M. The 52-week trading range was $2.30 to $209.03. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.